17 November 2017
Regulatory

MIFID II – Equity Research

With MIFID II soon to come into effect (3rd January, 2018), questions remain, what does this mean for the future of equity research and why should it matter to Australian investment firms?

A key component of MIFID II is the requirement for research to be explicitly priced, or “unbundled” from trading activity. Although the incoming regulation is solely an EU directive, it has far reaching global ramifications that are expected to cause a re-think by both the buy and sell side, of how research is consumed, paid for, and ultimately priced.

A McKinsey Report titled “Reinventing equity research as a profit-making business” (Jun 2017), paints an interesting picture of a post-MIFID II world, and sets out the scenarios that may evolve because of these changes.

https://www.mckinsey.com/industries/financial-services/our-insights/reinventing-equity-research-as-a-profit-making-business

Copy link

All material on this website has been prepared by MST Financial Services Pty Limited (ABN 54 617 475 180, AFSL 500 557) for general informational purposes only and is not a solicitation of any offer to buy or sell any financial instrument or to participate in any trading strategy. Unless otherwise stated, the material presented on this site is not a research report as defined under ASIC guidance. For wholesale clients only. This material is only prepared for wholesale clients pursuant to section 761G(7) of the Corporations Act (Commonwealth). Please also refer to MST's Privacy Policy, Terms of Use and Financial Services Guide.

Some of the products referred to on this website are issued by Equity Trustees Limited (ABN 46 004 031 298, AFSL 240975), the Responsible Entity of the funds. Equity Trustees is a subsidiary of EQT Holdings Limited (ABN 22 607 797 615), a company listed on the ASX (ASX: EQT). Before making any investment decision, you should carefully review the relevant disclosure documents, including the Product Disclosure Statement (PDS), Reference Guide (RG), and Target Market Determination (TMD), available from Equity Trustees. For MST Individually Managed Accounts (IMAs), please refer to the Information Memorandum. MST does not warrant the accuracy or completeness of the information provided and disclaims all liability for any errors or omissions, to the extent permitted by law. Past performance is not a reliable indicator of future performance.